drugset
drugset / Trial / NCT06545916

Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

NCT06545916 ↗

Phase 2 Completed 209 enrolled Knoa Pharma LLC Imbrium Therapeutics · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.

Timeline

Start
2024-10-14
Primary completion
2026-05-05
Completion
2026-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunobinop Small molecule — Oral

Indications

alcohol-related disorders